What we do:
Offspring Biosciences provides contract research services to the Pharma and Biotech industry, using advanced histopathology-based analytical techniques.
Who we are
The company is managed by Anders Ericsson-Dahlstrand, Dan Sunnemark and Anne Svensson, former senior scientists at AstraZeneca's now closed R&D unit in Södertälje, Sweden. We bring extensive and solid experience supporting drug discovery teams targeting neurodegenerative diseases (Alzheimers, Parkinsons and Huntingtons disease), diabetes and oncology, with highly informative and reliable data for critical Stop/Go decisions.
- Full study deliveries (design, execution, analyses and reporting)
- Target validation studies in tissues from pre-clinical disease models
and in human tissue
- Profiling of drug binding properties, including demonstrating target engagement and performing tissue cross reactivity analyses
- Evaluating effects in pre-clinical drug treatment studies
- Evaluating side effect risks
- Supporting translational research activites
- Animal and human tissue sourcing, validation and characterization
- Crititical review of literature data regarding quality, gap and risk
- Extended services via strategic collaborations (eg tissue banking, in vivo pharmacology, bioanalysis, radiochemistry, whole body autoradiography, human and veterinary pathology)
- Right Target
- Right Drug
- Right Efficacy
- Right Safety
For further information, please visit our website
Joint Stock Company Grindeks is an international, vertically integrated pharmaceutical company in the Baltic States, Latvia. The main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients.
The main therapeutic groups of Grindeks are cardiovascular, central nervous system, anti-cancer and diabetes medicines.
Current vacancies in Latvia: http://www.grindeks.lv/lv/karjera/grindeks-darba-piedavajumi
Mabion Poland S.A. is a leading biotechnology company that was created in order to market the latest generation of biotech drugs based on humanized monoclonal antibodies.
This technology, developed in Mabion by itself, is a high-tech at the highest level. The process of humanizing monoclonal antibodies, being the apex of today’s biotechnology enables the production of targeted drugs that act selectively on cancer cells, providing greater efficacy and lower toxicity of the therapy.
Mabion was created in March 2007 by four national pharmaceutical companies: Celon Pharma Łomianki, one of the leading cancer drugs in Poland, Polfarmex from Kutno, which is a national leader in the market of prescription medicines, IBSS Biomed from Krakow, Poland’s largest and counting the European manufacturer of vaccines and Genexo from Warsaw operating in the market of drugs and medical devices, mainly in the field of diabetes. Mabion also created two entities carrying out research in the field of biotechnology: BioCentrum and Biotech Consulting.
Within a few years Mabion competence possessed the manufacture of any biotechnological drugs from the design phase through the choice of platform and manufacturing technologies to produce the finished drug. Currently in its laboratories in Łódź, the company conducts research and development on a number of biotech drugs, used in the treatment of cancer and metabolic diseases.
AKRN Scientific Consulting is a clinical research and regulatory consulting firm for medical devices and IVD.
AKRN is based in Spain and Sweden.
We provide clinical development services on a stand-alone basis, or as part of an integrated full-service solution together with our European CRO-partners.
Our clients include MedTech start-up companies as well as multi-national companies.
We are committed to partner with Medical Device companies developing innovative technologies improving health care for more people.
We are highly qualified, experienced, and accountable clinical research professionals that guarantee cost-effective and successful solutions crafted to each client’s needs. We combine therapeutic expertise and decades of industry know-how with excellent service and responsiveness to support our customers with solutions that can stand up to rigorous scientific and regulatory evaluations.
We follow the national and international current standards (ICH/GCP guidelines, European regulations, and national and regional legislation), and the client or AKRN internal SOPs.
-Clinical Trial Services
-Clinical Strategy and Planning
-Post Market Clinical Follow Up PMCF
-CE Mark Strategic Planning
-Technical File | Design Dossier
-EU MDD to MDR Transition
-EU IVDD to IVDR Transition
-Clinical Evaluation Report CER
At Julius Clinical, science is the foundation. Combined with flexibility, creativity, and innovation, our scientific approach enables fast, efficient, and high quality execution of complex clinical development programs. Our skilled and loyal networks of investigators all around the world allow us to offer superior recruitment in therapeutic area’s such as cardiology, diabetes, CNS and infectious diseases.
Our partners include leading pharmaceutical, biotech, medical device, and food companies, as well as academic investigators. We focus on clinical trials that are likely to have a major impact on medicine and on people’s lives. This type of demanding research requires more than a ‘one-size-fits-all’ approach, and our fusion of scientific and operational expertise enables to deliver results efficiently, on time and budget.
Julius Clinical has on its staff internationally recognised academic leaders who are actively involved in the design, conduct, and interpretation of clinical trials. This scientific expertise and credibility, combined with personal links with peers around the world, means that the company has a truly global reach and reputation. Through our global networks we can quickly select the most appropriate and high-performing sites to take part in a trial, and ensure that investigators are inspired and motivated.